Introduction
With improvements in early detection and treatments for malignancy, patients with malignancy are living longer and more often with complete recovery from malignancy or with malignancy under control. As a result, malignancy is increasingly being recognized as a chronic disease. The growing cohort of survivors that exceeds 10 million was recently reported. 1 The incidence of aortic stenosis (AS), which was accompanied with degenerative changes, is also increasing. 2 The prevalence of severe AS may be up to 4.6% and 8.1%
in people aged 75 or older and aged 85 or older, respectively. [2] [3] [4] Thus, prolonged life expectancies of patients with malignant disease enabled simultaneous development of AS. However, information on the influence of malignancy on the outcomes of patients with severe AS 5-8 is limited. There have been few opportunities to study this topic because of the exclusion criterion of randomized controlled trial and the benefit from therapy to AS being blunted by malignancy-related death. Recently, we reported an observational registry which enrolled all consecutive patients who met the criteria of severe AS in a multicentre fashion. [9] [10] [11] The aim of the present study was to investigate the effect of active and inactive malignancies on the outcomes of severe AS. Furthermore, we examined the reasons of the management strategies in patients with AS and malignancy as well as the perioperative complications of patients who underwent surgery for the malignancy.
Methods Patients
We enrolled 3815 patients with severe AS from 27 centres in Japan between January 2003 and December 2011 in the Contemporary outcomes after sURgery and medical tREatmeNT in patients with severe Aortic Stenosis (CURRENT AS) registry (Supplementary material online, Appendix). 9 Using the hospital database for transthoracic echocardiog- ] for the first time during the study period were enrolled in this registry. 9 When stratified according to the initial treatment strategies after the index echocardiography, the entire cohort was divided into the conservative management cohort (n = 2618) and initial AVR cohort (n = 1197). The decision of the initial treatment strategy was based on the physicians' discretion. Study design and patient enrolment in the registry have been previously described in detail. 9 The study protocol was approved by the institutional review board of each participating centre. The requirement of written informed consent was waived due to the retrospective nature of the study. Patient records were anonymized prior to analysis.
Definitions of malignancy status and other conditions
The study subjects were divided into three groups based on the malignancy status. We defined the malignancy group as those with a malignancy currently under treatment, for which treatment is planned, or the best possible supportive care is being provided, whereas the past history group was defined as those with a history of malignancy but without the need for current treatment. No malignancy group was defined as those without a history of malignancy ( Figure 1) . Malignancy types were classified according to anatomic and system primary involvement. 12 The date of first malignancy diagnosis was identified from the hospital record. Reasons for selecting each treatment strategy were placed into one of the various categories in the malignancy group; however, detailed reasons allowed for overlaps. We defined anaemia according to the World Health Organization criteria (haemoglobin < 13.0 g/dL in men and <12.0 g/dL in women). Results of two-dimensional transthoracic echocardiography were analysed at index echocardiography. The left ventricular ejection fraction (LVEF) was measured using the Teichholz method or the modified Simpson's rule method.
Outcome measures
The primary outcome measure for the present analysis was all-cause death during the 3-year follow-up period. The secondary outcome Aortic valve-related death included aortic procedure-related death, sudden death, death caused by heart failure (HF) potentially related to the aortic valve, and death due to aortic valve endocarditis. Sudden death was defined as death within 24 h after the manifestation of symptoms, death during sleep, or unwitnessed death in patients who had been stable until then. When obvious non-cardiogenic causes were identified, the deaths were excluded from the definition of sudden death.
Statistical analysis
In the present analysis, (i) we compared the baseline characteristics and 3-year clinical outcomes among the three groups on the basis of malignancy status in the entire cohort and each treatment strategy, (ii) we investigated the reasons behind selecting each treatment strategy for AS in the malignancy group, and (iii) we compared perioperative complications of the surgery for malignancy between those patients with or without AVR before malignancy surgery. The categorical variables were expressed as numbers and percentages and were compared using a v 2 test or Fisher's exact test. Continuous variables were expressed as mean ± standard deviation or median with interquartile range (IQR). On the basis of their distribution, continuous variables were compared using the Student's t-test or the Wilcoxon rank sum test between the two groups and the one-way analysis of variance or Kruskal-Wallis test across the three groups. To compare the 3-year clinical outcomes among the three groups in the entire cohort and each treatment strategy, the probability of all-cause death was estimated using the Kaplan-Meier method; the log-rank test was used for univariate comparisons. Cumulative incidence rates of malignancy-related or aortic valve-related death were estimated by using the Gray method, 15 accounting for the competing risk of death other than malignancy-related death or aortic valve-related death, respectively. To estimate the risk of the malignancy group and past history group relative to the no malignancy group during the entire follow-up period, a multivariable Cox proportional hazards model was developed for the allcause death, and multivariable Cox proportional hazards models described by Fine and Gray subdistribution hazard model 16 were developed for the malignancy-related death and aortic valve-related death according for the competing risk of death other than malignancy-related death or aortic valve-related death, respectively. The results were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). We selected 22 clinically relevant risk-adjusting variables ( Table 1) by using dummy variables, with the centre incorporated as the stratification variable. This was consistent with our previous study, 9 except for the addition of admission for HF as a risk-adjusting variable. The subgroup analyses for the primary and secondary outcome measures were also performed in the conservative management cohort and the initial AVR cohort according to the intention-to-treat principle, regardless of the actual performance of AVR. All statistical analyses were conducted by a physician (E.M. or T.K.) and a statistician (T.M.) using JMP 10.0.2 or SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All the reported P-values were two-tailed, and the level of statistical significance was set at P < 0.05.
Results

Baseline clinical and echocardiographic characteristics
Among the 3815 patients, 124 patients had malignancy currently under treatment, for which treatment was planned, or the best supportive care was being provided (malignancy group), 389 had a past history of malignancy (past history group), and 3302 patients had no history of malignancy (no malignancy group) ( Figure 1 ). Regarding the baseline characteristics, patients in the malignancy group were more often male and had a higher prevalence of low body mass index, recurrence of malignancy, diabetes on insulin therapy, anaemia, chest wall irradiation, and liver cirrhosis, whereas they had lower prevalence of hypertension, aortic/peripheral vascular disease, and symptoms related to AS ( Table 1) . Surgical risk scores were comparable among the three groups. All echocardiographic parameters except the left ventricular posterior wall thickness were comparable across the three groups. Initial AVR strategy was least often taken in the malignancy group ( Table 1) . Malignant disease as a comorbidity in patients with severe aortic stenosis
Clinical outcomes
The median follow-up duration after the index echocardiography was 1176 (IQR: 733-1618) days, with a 93% follow-up rate at 2 years. The cumulative 3-year incidence of AVR/TAVI was significantly lower in the malignancy group (24.4%) than in the past history group and no malignancy groups (past history group: 46.3%, no history group: 49.5%; P < 0.001) (Figure 2A) . During the follow-up, 25 patients were undergoing AVR (n = 24)/TAVI (n = 1) in the malignancy group, 164 patients were undergoing AVR (n = 159)/TAVI (n = 5) in the past history group, and 1555 patients were undergoing AVR (n = 1521)/TAVI (n = 34) in the no history group. The proportion of patients undergoing TAVI to surgical AVR/TAVI was not different among the three groups (P = 0.66). The cumulative 3-year incidence of the primary outcome measure (all-cause death) was markedly higher in the malignancy group and slightly but significantly higher in the past history group than in the no history group (64.9%, 39.0%, and 28.4%; P < 0.001) ( Figure 2B ). The cumulative 3-year incidence of malignancy-related death was also markedly higher in the malignancy group than in the past history group and the no history group (36.4%, 8.6%, and 1.7%; P < 0.001) ( Figure 2C ), whereas the cumulative incidence of aortic valve-related death did not differ significantly among the three groups ( Figure 2D ). After adjusting for confounders, the excess risk in the malignancy group and past history group relative to the no malignancy group for all-cause death remained significant (HR 2.49, 95% CI 1.98-3.14; P < 0.001 and HR 1.23, 95% CI 1.04-1.46; P = 0.01, respectively; Supplementary material online, Table S1 ). In malignancy-related death, the excess risks in the malignancy and past history groups relative to the no malignancy group were significant (HR 16.2, 95% CI 10.64-24.54; P < 0.001 and HR 3.66, 95% CI 2.43-5.52; P < 0.001, respectively) (Supplementary material online, Table S1 ). For aortic valve-related death, the risk in the malignancy group was comparable to that in the no malignancy group (HR 0.79, 95% CI 0.48-1.29; P = 0.35), whereas the risk of the past history group was lower than that in the no malignancy group (HR 0.72, 95% CI 0.53-0.96; P = 0.03) (Supplementary material online, Table S1 ).
Subgroup analysis according to the treatment strategy
In the conservative management cohort (n = 2618, Supplementary material online, Table S2), the results of cumulative 3-year incidence of the primary and secondary outcome measures among the three groups and the excess risk of the malignancy group were consistent with those in the entire cohort (Supplementary material online, Figure S1A -D and Table S3 ). In the initial AVR cohort (n = 1197, Supplementary material online, Table S4), the cumulative incidence of surgical AVR or TAVI did not differ among the three groups categorized by malignancy status (Supplementary material online, Figure S2A ). No patient had aortic valve-related death in the malignancy group (Supplementary material online, Figure S2B -D and Table S5 ). The proportion of patients undergoing TAVI to surgical AVR/TAVI did not differ among the three groups in the conservative management and initial AVR cohorts (P = 0.51, P = 0.20, respectively) (Supplementary material online, Table S6 ).
Reasons for selecting treatment strategies in the malignancy group
In the malignancy group, AVR was selected as the first-line treatment in 16 of 124 patients (12.9%). In the past history group, AVR was selected for 114 of 389 patients (29.3%), whereas 1067 of 3302 patients (32.3%) in the no malignancy group received AVR as the firstline treatment (Figure 1 ). In the malignancy group, the most common types of the malignancies were prostate cancer (n = 24; 19.4%), lung cancer (n = 19; 15.3%), gastric cancer (n = 13; 10.5%), hepatic cancer (n = 8; 6.5%), and breast cancer (n = 8; 6.5%) (Supplementary material online, Table S7 ). The presence of metastasis was recognized in 38 patients. Seventy-eight patients were recognized as not having metastasis, and six patients were of unknown status. The cumulative incidence of AVR/TAVI was not statistically significant between the groups with and without metastasis (Supplementary material online, Figure S3A ), but the incidence of the overall mortality and malignancyrelated death was higher in the group with metastasis (Supplementary material online, Figure S3B and C). Table 2 summarizes the reasons behind selecting conservative management or AVR/ TAVI in the malignancy group. In the conservative management cohort, absence of symptoms was the most common reason, limited life expectancy due to diseases unrelated to AS was the second, and age was the third common reason behind selecting conservative management. Six patients declined the AVR/TAVI. In the AVR cohort, the reasons were symptomatic, as well as requirement of AVR before non-cardiac surgery, and very severe AS.
Perioperative complications of surgery for malignancy
Surgery for malignancy was performed in 35 patients with malignancy. We presented the characteristics and perioperative complications in patients undergoing surgery for malignancy in Table 3 . Surgery was performed on 30 patients for malignancy before or without AVR/TAVI and five patients after AVR/TAVI. Three patients (43%) who underwent surgery for malignancy after AVR/TAVI had very severe AS, whereas only one patient (3%) with surgery for malignancy before or without AVR/TAVI had very severe AS. Society of Thoracic Surgeon (STS) scores were comparable. There were no procedure complications within 30 days in both groups. One patient died within 30 days of the surgery for malignancy before or without AVR/TAVI group, and the death was malignancy-related death.
Discussion
The main findings of this study are as follows: (i) malignancy had a marked effect on all-cause mortality and malignancy-related mortality and was associated with a lower rate of AVR/TAVI; (ii) past history of malignancy had a smaller but significant effect on these mortalities but no substantial effect on the rate of AVR/TAVI; (iii) in patients with malignancy, the main reasons behind selecting AVR/TAVI strategy were HF symptoms and severity of AS, whereas the common reasons for the choice of conservative treatment strategy were high operative risk and limited life expectancy; and (iv) the rates of perioperative complications and mortality for malignancy surgery were low both in patients before or without AVR/TAVI and in patients who had underwent AVR/TAVI prior to malignancy surgery.
Multiple models have been developed to predict accurately operative and early mortality following aortic valve 17 and heart surgery, [18] [19] [20] [21] but none of these models has considered the additional complexity related to a malignancy diagnosis. Moreover, no differences in STS scores were found among the three groups classified according to the presence of malignancy. Patients with AS and malignancy were less likely to have symptoms of AS. One reason for this might be that the malignancy status may mask the symptoms of AS through decreased physical activity, which is common in patients with malignancy. Another reason might be related to the screening of cardiovascular disease in patients with malignancy, leading to the diagnosis of severe AS without symptoms. Despite the lack of malignancy in the operative risk models, our data may support that clinically relevant choices had been made for the surgical AVR or conservative management in patients with malignancy, considering the relatively low rate of malignancy-related mortality in the AVR cohort. Another consideration is that terminally ill patients may not have undergone echocardiography initially and may not have been identified to be included in this study. There might be patients with malignancy and severe AS who had not undergone echocardiography as it had not been recognized by their oncologists or who felt that further investigation was not required due to the prognosis from their malignant disease, as this was an observational study based on the hospital database for transthoracic echocardiography.
The malignancy group also showed high mortality due to malignancy. In clinical practice, the presence of malignancy in patients with severe AS is often considered a contraindication to surgical aortic valve replacement. 22 The recent progress in TAVI has allowed extending the overall life expectancy of patients with malignancy to more than 1 year. 7 However, it is difficult to determine the length of life expectancy permitting TAVI. We also considered decreased daily life activities, which are due to malignancy or AS, as well as other surgical risk when accounting for TAVI indication. The past history of malignancy had a small but a significant effect on mortality. It was mainly due to the increase of malignancy-related death. Various studies reported that anti-cancer drug had cardiotoxicity and increase the risk of HF. 23, 24 In our study, there were no differences in cardiac function or pressure gradient among the three groups. On the basis of competing risk model, the risk of aortic valve-related death was lower in the past history group. Close attention to the potential recurrence of malignancy or newly developed malignancy might decrease aortic valve-related death through frequent contact with health care providers in the past history group.
There is a paucity of data on the safety of the surgery for malignancy in the presence of severe AS. Malignant disease might cause serious perioperative complications such as bleeding 25 due to vulnerable tissue and infection 26 due to cachexia if AVR was performed in the presence of malignancy. In addition, invasive AVR might cause the delay of the treatment of malignancy. In this study, we evaluated the perioperative complications in patients who underwent malignancy surgery in the presence of severe AS ('malignancy first' strategy) and in those who underwent malignancy surgery after AVR ('AVR first' strategy) in the registry data. We could not draw solid conclusions due to the small number of patients, although there were no significant differences in the rate of perioperative complications. A prospective study by Watanabe et al. 7 in Japan reported that patients with malignancy with severe AS who underwent TAVI had similar 1-year mortality as patients without malignancy. In contrast, another prospective study by Mangner et al. 27 reported that malignancy in patients undergoing TAVI more adversely affected 1-year mortality compared with that in those with a history of malignancy and controls without known malignant disease. This discrepancy might be due to variances in malignancy type distribution and racial disparities. 28 Further studies, which are retrospective or prospective, are needed to answer the questions about what malignancy type, malignancy stage, and level of surgical invasiveness would allow each strategy. The process of decision-making for the treatment strategy is complicated in patients whom malignant disease and cardiac disease coexist because the prognosis and cardiovascular complications of malignancy therapy vary depending on the malignancy type, stage, and therapy. As some patients with long-term thoracic radiation therapy have radiation-related pericardial fibrosis, 29 TAVI might be an indication for such patients. 30, 31 It is necessary to decide treatment strategy considering various factors based on the perspectives from cardiovascular physicians, cardiac surgeons, oncologist, and radiologist. There is a report that incidental findings of tumour in a computer tomography before undergoing TAVI did not have a significant effect on the outcomes for elderly patients with severe AS based on the decision of the interdisciplinary heart team. 6 A heart team approach with oncologists and radiologist can make clinically relevant decisionmaking easier and reduce the perioperative complications. Thus, it is important to investigate contemporary data when we consider the choice of 'TAVI first' strategy, 'surgical AVR first' strategy, or 'malignancy first' strategy in patients with AS and malignancy for optimizing treatment through the heart team approach.
Limitations
First, the precise staging and lines of prior chemotherapy were not collected; therefore, we could not analyse the data according to malignancy staging or therapy. Second, the exact expected life expectancy of each patient in the malignancy group was unclear. However, a substantial portion of patients was estimated to have a limited life expectancy in the malignancy group. Third, categorization of the circumstances surrounding each death, particularly the mechanism of death, was related to the process of adjudication and may be incomplete. It is unclear whether sudden death or endocarditis is due to pulmonary embolism or endocarditis related malignancy. Fourth, we did not collect the data about a heart team approach nor the referral for oncologists. Fifth, there remain unmeasured confounders affecting the mortality, although we conducted extensive statistical adjustment for the measured confounders. Sixth, the number of patients in the malignancy group according to the initial treatment strategy and number of patients who underwent surgery for the active malignancy with severe AS were very small. However, in conjunction with other reports, our data shed light on the practice for the complicated conditions of patients with malignancy and severe AS. Seventh, the number of patients undergoing TAVI in our study was too small to analyse the difference between the patients undergoing TAVI and AVR. Finally, although this study was based on a registry in Japan, the prevalence of malignancy might be different depending on the countries and race. The external validity should be confirmed to further investigate this issue, and a study in another country or race is required.
Conclusion
Active malignancy had a marked effect on all-cause death and malignancy-related death in patients with severe AS. History of malignancy also had a smaller but significant effect on mortality. 
